A breakthrough in Alzheimer’s disease has arrived with the introduction of C2N Diagnostics’ PrecivityAD blood test. Researchers at C2N have found the PrecivityAD test predicts Alzheimer’s brain pathology in people with memory and thinking issues.
Based on data from 686 patients aged over 60 with subjective cognitive impairment or dementia, the PrecivityAD test correctly identified brain amyloid plaque status (as determined by quantitative amyloid PET scans) in 86% of the patients. The Receiver Operating Characteristic (ROC) for the analysis had an area under the curve (AUC) of 0.88.
The proprietary test involves a small blood sample. C2N analyses the blood in its specialised laboratory facility using mass spectrometry to measure the concentrations of amyloid beta 42 and 40 (Aß42 and Aß40), and the presence of apolipoprotein E (ApoE) isoforms in blood. The analysis process is automated and allows C2N to process samples in a routine and repeatable manner.
Further details of the test’s diagnostic performance are provided here.
